SNPMiner Trials by Shray Alag

SNPMiner SNPMiner Trials (Home Page)

Report for Clinical Trial NCT01385722

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Molecular Analysis of Thoracic Malignancies

A research study to learn about the biologic features of cancer development, growth, and spread. We are studying components of blood, tumor tissue, normal tissue, and other fluids, such as urine, cerebrospinal fluid, abdominal or chest fluid in patients with cancer. Our analyses of blood, tissue, and/or fluids may lead to improved diagnosis and treatment of cancer by the identification of markers that predict clinical outcome, markers that predict response to specific therapies, and the identification of targets for new therapies.

NCT01385722 Thymus Cancer Thymoma Thymic Carcinoma Lung Cancer Carcinoma, Non-Small-Cell Lung Mesothelioma
MeSH:Carcinoma Mesothelioma Carcinoma, Non-Small-Cell Lung Thymoma Thymus Neoplasms
HPO:Carcinoma Neoplasm of the thymus Non-small cell lung carcinoma Thymoma

Primary Outcomes

Measure: Collect detailed clinical information on patients with thoracic malignancies via the electronic medical record and a detailed patient questionnaire

Time: 20 years

Time Perspective: Prospective


There is one SNP


1 L858R

Over 90% of EGFR tyrosine kinase domain mutations associated with sensitivity to EGFR Tyrosine kinase inhibitor (TKI) therapy fall into two categories, in-frame deletions in exon 19, and the L858R point mutation in exon 21. --- L858R ---

HPO Nodes